Onset of Action of Azelastine Nasal Spray Compared to Mometasone Nasal Spray and Placebo in Patients with Seasonal Allergic Rhinitis (SAR)

Levocabastine and azelastine are currently the only antihistamines available as nasal sprays for the topical therapy of seasonal allergic rhinitis. The present study was undertaken to compare the onset of action, efficacy and tolerability of these two agents in a total of 242 patients with this condition. This was an international, multicentre, open-label, randomized, parallel-group trial with 123 patients treated with levocabastine (0.5 mg/ml, two puffs per nostril twice daily) and 119 with azelastine (1 mg/ml, one puff per nostril twice daily). Onset of action was comparable for the two drugs with over 50% of patients in each group reporting significant symptomatic relief within 30 min of administration of the first dose of study medication. Therapeutic efficacy was also found to be comparable in the two groups with no statistically significant intergroup differences reported for any of the parameters evaluated, although assessments of global therapeutic efficacy revealed a trend favouring levocabastine. Levocabastine appeared to be better tolerated than azelastine (p = 0.06), with the incidence of the most common adverse experiences, application site reactions and taste disturbances, significantly higher on azelastine than with levocabastine (5% versus 1%; p = 0.05 and 5% versus 0%; p = 0.01, respectively). In conclusion, levocabastine nasal spray appears to be at least as effective as, but better tolerated than, azelastine nasal spray for the treatment of seasonal allergic rhinitis.

Download Full-text

Onset of Action of Azelastine Nasal Spray Compared with Mometasone Nasal Spray and Placebo in Subjects with Seasonal Allergic Rhinitis Evaluated in an Environmental Exposure Chamber

American Journal of Rhinology ◽

10.2500/ajr.2007.21.3058 ◽

2007 ◽

Vol 21 (4) ◽

pp. 499-503 ◽

Cited By ~ 43

Author(s):

Piyush Patel ◽

Carrie D'Andrea ◽

Harry J. Sacks

Keyword(s):

Allergic Rhinitis ◽

Environmental Exposure ◽

Nasal Spray ◽

Seasonal Allergic Rhinitis ◽

Allergen Challenge ◽

Nasal Symptom ◽

Exposure Chamber ◽

Onset Of Action ◽

Environmental Exposure Chamber ◽

Time Point

Background The objective of this study was to determine the onset of action of azelastine hydrochloride nasal spray compared with placebo and an intranasal steroid, mometasone furoate, in subjects with seasonal allergic rhinitis (SAR). Methods Subjects with a history of SAR and symptomatic while exposed to ragweed pollen in an environmental exposure chamber (EEC) were randomized to azelastine nasal spray (n = 150), mometasone nasal spray (n = 150), or placebo (n = 150) and recorded total nasal symptom scores (TNSS), consisting of sneezing, nasal pruritus, rhinorrhea, and congestion, during an 8-hour study period. Results Azelastine nasal spray showed a statistically significant improvement in the TNSS at 15 minutes compared with placebo. The effect was durable at each time point during the 8-hour study. Azelastine nasal spray also was significantly more effective than mometasone at each time point. Conclusion Azelastine nasal spray has a rapid (15 minute) onset of action. Azelastine nasal spray was superior to both placebo and mometasone nasal spray in reducing nasal symptoms of SAR occurring within 8 hours after an allergen challenge.

Download Full-text

Rapid Nasal Symptom Onset of Action and Ocular Symptom Relief With Olopatadine/Mometasone Combination Nasal Spray in Patients with Seasonal Allergic Rhinitis: A Pooled Analysis

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2018.12.190 ◽

2019 ◽

Vol 143 (2) ◽

pp. AB62 ◽

Cited By ~ 1

Author(s):

Bruce Prenner ◽

Frank Hampel ◽

Nelumka Fernando ◽

Cynthia F. Caracta ◽

Sudeesh K. Tantry

Keyword(s):

Allergic Rhinitis ◽

Nasal Spray ◽

Symptom Onset ◽

Seasonal Allergic Rhinitis ◽

Symptom Relief ◽

Pooled Analysis ◽

Nasal Symptom ◽

Ocular Symptom ◽

Onset Of Action

Download Full-text

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Case Medical Research ◽

10.31525/ct1-nct03861559 ◽

2019 ◽

Author(s):

Keyword(s):

Allergic Rhinitis ◽

Nasal Spray ◽

Seasonal Allergic Rhinitis ◽

Mometasone Furoate ◽

Onset Of Action

Download Full-text

Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy

Current Medical Research and Opinion ◽

10.1185/030079906x80305 ◽

2005 ◽

Vol 22 (1) ◽

pp. 151-157 ◽

Cited By ~ 52

Author(s):

Friedrich Horak ◽

Ursula Petra Zieglmayer ◽

René Zieglmayer ◽

Alexander Kavina ◽

Kristina Marschall ◽

...

Keyword(s):

Allergic Rhinitis ◽

Nasal Spray ◽

Seasonal Allergic Rhinitis ◽

Onset Of Action ◽

Pharmacodynamic Study

Download Full-text

A Comparison of the Efficacy of Azelastine Nasal Spray and Loratidine Tablets in the Treatment of Seasonal Allergic Rhinitis

Journal of International Medical Research ◽

10.1177/030006059302100505 ◽

1993 ◽

Vol 21 (5) ◽

pp. 268-275 ◽

Cited By ~ 17

Author(s):

R Gambardella

Keyword(s):

Allergic Rhinitis ◽

Nasal Spray ◽

Seasonal Allergic Rhinitis ◽

Rating Scale ◽

Sono State ◽

Rapid Onset ◽

Onset Of Action ◽

Double Blind ◽

Treatment Groups ◽

Sono Stati

A total of 30 patients suffering from seasonal allergic rhinitis were treated in a 6-week randomized, double-blind, double-dummy parallel-group study, comparing azelastine nasal spray (0.14 mg/nostril administered twice daily) and loratidine tablets (10 mg once daily). Symptoms evaluated were sneezing, nose and/or eye itching, lacrimation, rhinorrhoea, photophobia, nasal occlusion, throat irritation, smell loss, nasal mucosa swelling, conjunctivitis, and pharyngeal mucosa reddening. Each symptom was assessed according to severity and given a score on a fourpoint rating scale. Compared with baseline, total symptom scores for both the azelastine and loratidine treatment groups were reduced at each of the assessments during treatment. No significant differences were observed between the two treatment groups. The investigator concluded that azelastine, formulated as a nasal spray, is as effective as loratidine tablets in the relief of the symptoms of seasonal rhinitis and that it has a rapid onset of action. Un gruppo di 30 pazienti affetti da rinite allergica stagionale è stato trattato, in uno studio radomizzato, tra gruppi paralleli, doppio cieco, double dummy della durata di 6 settimane con azelastina spray nasale (0.14 mg/narice 2 volte al giorno) e loratina compresse (10 mg/die). I sintomi controllati sono stati i seguenti: starnuti, prurito nasale e/o oculare, lacrimazione, rinorrea, fotofobia, occlusione nasale, irritazione faringea, perdita dell'olfatto, edema della mucosa nasale, congiuntivite ed arrossamento della mucosa faringea. I sintomi sono stati valutati in base alia loro gravità assegnando un punteggio variabile da 1 a 4. In entrambi i gruppi di trattamento il punteggio totale della sintomatologia è risultato inferiore a quello basale ad ogni controllo nel corso dei trattamenti. Non sono state rilevate differenze significative tra i due trattamenti che si sono dimostrati entrambi efficaci. I ricercatori hanno concluso che azelastina spray nasale ha la stessa efficacia di loratidina compresse nell'alleviare i sintomi della rinite allergica stagionale e possiede una notevole rapidità di azione ed una notevole maneggevolezza clinica.

Download Full-text